<!DOCTYPE html>
<html>
	<head>
		<link rel="stylesheet" href="main.css">
		<title>ME/CFS Research</title>
	</head>
	<body>
		<div class="main">
			<h1><a href="/">ME/CFS Research</a> :: Treatments</h1>
			<hr class="styled top">
			<div class="main-column">
				<h2>Treatments</h2>
				<p class="passage">
					The following are trialed, proposed, hypothetical, speculative, or imaginary treatments.
					These are not meant as treatments for patients to try but ideas for clinical trials
					and trial updates.
				</p>

<h4><u>Proposed or Speculative Repurposed Drugs</u></h4>
<ul>
	<li>For Orthostatic Hypotension and/or Exercise Intolerance
		<ul>
			<li>droxidopa (Northera)</li>
				<li>midodrine</li>
				<li>fludrocortisone</li>
				<li>pyridostigmine (Mestinon)</li>
		</ul>
	</li>
	<li>For Cerebral Blood Flow
		<ul>
			<li>sildenafil (Viagra)
				<ul>
					<li><a href="https://grantome.com/grant/NIH/P20-RR011145-14S2-6918">hypothesis</a></li>
					<li><a href="https://clinicaltrials.gov/study/NCT00598585">clinical trial completed</a></li>
					<li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9127063/">may improve neurologic and endothelial function and inflammation after brain injury</a></li>
					<li><a href="https://journals.lww.com/clinicalneuropharm/abstract/2008/11000/role_of_sildenafil_in_neurological_disorders.6.aspx">neurological adverse events</a></li>
					<li><a href="https://x.com/organichemusic/status/1591421636154204160">X discussion</a></li>
				</ul>
			</li>
		</ul>
	</li>
	<li>low dose naltrexone (LDN) â€“ possible immune modulator, has other effects</li>
	<li>low dose aripiprazole (Abilify)</li>
	<li>Immunomodulators/Monoclonal Antibodies
		<ul>
			<li>rituximab (successful Phase II trial, failed Phase III trial)</li>
			<li>cyclophosphamide (Fluge & Mella)</li>
			<li>daratumumab (Fluge & Mella)</li>
			<li>subcutaneous ofatumumab (Kesimpta) (speculative)</li>
			<li>next-generation CD20-targeted B cell-depleting antibodies, e.g. obinutuzumab, ocrelizumab and ofatumumab)<br>
				(these deplete both blood and tissue B cells more efficiently than rituximab)<br>
				(proposed by W Robinson et al for autoimmune diseases)<br>
			</li>
		</ul>
		<li>rapamycin (Rapamune/Sirolimus) (D Peterson)
			(<a href="https://clinicaltrials.gov/study/NCT06257420">clinical trial ongoing</a>)
		</li>
		<li>JAK inhibitors, e.g. tofacitinib (Xeljanz) and baricitinib (Olumiant)</li>
		<li>abatacept or drugs that inhibit antigen presentation</li>
		<li>checkpoint inhibitors to clear peristent pathogens<Br>
			(might cause autoimmunity or rheumatic disease, highly inadvisable outside official clinical trial)
		</li>
		<li>IVIG</li>
		<li>leflunomide or teriflunomide (anti-rheumatic/immune suppressant, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5546479/">EBV inhibitor</a>)
	<li>
		Antivirals (new trials should be a minimum 9 months, preferably 12 months)
		<ul>
			<li>valacyclovir (Valtrex)</li>
			<li>famciclovir (Famvir)</li>
			<li>valganciclovir (Valcyte)</li>
			<li>cidofovir (Vistide)</li>
			<li>brincidofovir (Tembexa / CMX001)</li>
			<li>artesunate</li>
			<li>tenofovir disoproxil fumarate (speculative)</li>
			<li>tenofovir alafenamide (speculative)</li>
		</ul>
	</li>
</ul>

<h4 style="text-align: left;"><u>Proposed or Speculative Combination Protocols</u></h4>
<ul>
    <li>LDN + pyridostigmine (proposed by D Systrom, <a href="https://clinicaltrials.gov/study/NCT06366724">clinical trial ongoing</a>)</li>
    <li>rituximab + anti-EBV drug (proposed by N Klimas & T Craddock, no known plans for trial)</li>
    <li>rituximab + IVIG (<a href="https://pubmed.ncbi.nlm.nih.gov/30072982/">proposed by A Ahmed</a> for generalized autoimmune disease)</li>
  <li>EBV reactivation agent (e.g. valproic acid) + anti-EBV drug<br>
    (highly speculative, could instigate autoimmunity)</li>
  <li>bone marrow transplant (highly speculative, dangerous)</li>
</ul>


<h4 style="text-align: left;"><u>Under Development</u></h4>
<ul>
	<li>Berlin Cures BC007</li>
	<li>Mitodicure MDC002</li>
	<li>Inspiritol (nebulized inhaled glutathione and other ingredients)</li>
	<li>WinSanTor WST057 (topical pirenzepine) (being developed for peripheral neuropathy)</li>
	<li>Ampligen (rintintolimod / poly i:poly c12u)</li>
    <li>Immunoadsorption (trial in Germany)</li>
</ul>

<h4 style="text-align: left;"><u>Imaginary</u></h4>
<ul>
  <li>Anti-CD21 antibody (to eliminate EBV infected cells and vulnerable cells)</li>
</ul>




			</div>
			<hr class="styled bottom">
			<p style="text-align:right; padding: 0; margin:0; font-size:80%;">Last Update: 21 October 2024</p>
		</div>
	</body>
</html>
